How India Exports Dextromethorphan to the World

In the United States, dextromethorphan is primarily marketed as an over-the-counter (OTC) medication for cough suppression. The FDA's OTC Drug Review has established a monograph for cough and cold preparations, under which dextromethorphan is recognized as generally safe and effective when used according to labeled instructions. Consequently, specific Abbreviated New Drug Applications (ANDAs) for dextromethorphan products are not typically required, as long as the products comply with the established monograph standards.

Regarding import regulations, the FDA mandates that all foreign drug establishments manufacturing dextromethorphan products intended for the U.S. market must register with the agency and list all their drug products in commercial distribution. This ensures compliance with FDA regulations and facilitates the importation process. Importers are required to file an entry notice and an entry bond with U.S. Customs and Border Protection, pending FDA's decision on the product's admissibility. As of March 2026, there are no specific FDA import alerts related to dextromethorphan products from India, indicating a favorable compliance status among Indian exporters.

In the European Union, dextromethorphan is authorized for use in various cough and cold preparations. The European Medicines Agency (EMA) oversees the approval and monitoring of these medicines. Notably, Nuedexta, a combination of dextromethorphan and quinidine, was granted marketing authorization on June 24, 2013, for the treatment of pseudobulbar affect in adults. However, the marketing authorization was withdrawn on February 15, 2016, at the request of the marketing authorization holder, Jenson Pharmaceutical Services Ltd, due to commercial reasons. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates dextromethorphan-containing products. These products must comply with the UK's specific marketing authorization requirements, including adherence to Good Manufacturing Practice (GMP) standards. Manufacturers exporting to the UK must ensure their facilities meet these GMP requirements to gain and maintain market access.

Dextromethorphan is included in the 20th edition of the WHO Model List of Essential Medicines, published in April 2017. This inclusion underscores its recognized efficacy and safety profile for the treatment of cough. (wkc.who.int) Additionally, dextromethorphan formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and therapeutic efficacy across different markets.

In India, dextromethorphan is classified as a Schedule H drug under the Drugs and Cosmetics Act, 1940, indicating that it is a prescription-only medication. However, certain formulations and dosages are available over-the-counter, subject to specific regulatory provisions. The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines, but as of March 2026, dextromethorphan is not listed under the Drugs (Prices Control) Order (DPCO), implying no ceiling price is currently imposed. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Dextromethorphan's primary patents have long expired, leading to a competitive market with multiple generic formulations available globally. This generic competition has contributed to its widespread availability and affordability. However, specific formulations or combinations, such as Nuedexta (dextromethorphan and quinidine), may still be under patent protection, depending on the jurisdiction and patent filing dates.

In August 2019, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a periodic safety update report (PSUR) single assessment for dextromethorphan. The assessment led to variations in the product information to enhance safety communications. (ema.europa.eu)

In November 2024, the EMA completed a PSUR single assessment for a combination product containing dextromethorphan hydrobromide, pseudoephedrine hydrochloride, and triprolidine hydrochloride. The outcome was the maintenance of the current marketing authorization, indicating no significant safety concerns were identified. (ema.europa.eu)

In the same month, another PSUR single assessment was finalized for a combination of chlorphenamine, dextromethorphan hydrobromide, and paracetamol. The regulatory outcome was also maintenance, suggesting the continued safety and efficacy of the combination product. (ema.europa.eu)

These assessments reflect ongoing regulatory vigilance to ensure the safety and efficacy of dextromethorphan-containing products in the European market.

India's pharmaceutical industry, including the production of Dextromethorphan, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

In recent years, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic manufacturing of APIs and KSMs, aiming to reduce this dependency. However, as of March 2026, the scheme's impact on decreasing reliance on Chinese imports remains limited, with the pharmaceutical sector still vulnerable to external supply chain disruptions.

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters of Dextromethorphan account for 35.2% of total exports, with SUN PHARMACEUTICAL INDUSTRIES LIMITED leading at an 8.9% share. This moderate concentration indicates a relatively diversified supplier base, which can mitigate risks associated with over-reliance on a few suppliers.

Despite the PLI scheme's objectives to enhance domestic API production, the current supplier landscape for Dextromethorphan suggests that while there is some concentration, the risk of single-source dependency is not pronounced. Nonetheless, continuous monitoring is essential to ensure that no single supplier gains disproportionate market control, which could pose future risks.

The ongoing conflict in the Middle East, particularly the closure of the Strait of Hormuz since February 28, 2026, has severely disrupted global shipping routes. This strait is a critical chokepoint for global trade, and its closure has led to significant delays and increased shipping costs. Major shipping companies have suspended transits through the region, opting for longer routes around the Cape of Good Hope, adding 10–14 days and substantial costs to shipments.

These disruptions have cascading effects on the pharmaceutical supply chain, including the export of Dextromethorphan from India. Delays in shipping can lead to inventory shortages, increased costs, and challenges in meeting global demand. Additionally, heightened tensions between the U.S. and China could further complicate trade relations, potentially impacting the availability of APIs and KSMs sourced from China.

• Diversify API and KSM Sources: Actively seek alternative suppliers from different countries to reduce dependency on any single nation, particularly China.

• Enhance Domestic Production: Accelerate the implementation and scaling of the PLI scheme to strengthen domestic manufacturing capabilities for APIs and KSMs.

• Develop Contingency Shipping Plans: Establish alternative logistics strategies, including securing agreements with shipping companies for diversified routes and considering air freight options for critical shipments.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events that could impact supply chains, enabling proactive risk management.

• Strengthen Supplier Relationships: Foster strong partnerships with multiple suppliers to ensure flexibility and resilience in the supply chain.

RISK_LEVEL: MEDIUM